The MPN News feed provides frequent updates on the latest happenings in the MPN World. Fresh content, with brief summary is automatically updated frequently from reliable sources. Â Just click on the red hyperlink to pull up the complete news item.
Make PV Reporter your “starting point” for all MPN related news.
- Mutations in the miR-142 gene are not common in myeloproliferative neoplasmsby mpn_admin at 4:33 pm
Authors: Paulina Galka-Marciniak, Zuzanna KanduÅ‚a, Adrian Tire, Wladyslaw Wegorek, Kinga Gwozdz-Bak, Luiza Handschuh, Maciej […]
- Flyer for Conference 2023by JOANN MANNINO at 12:00 am
Flyer for 13th Joyce Niblack Memorial Conference The post Flyer for Conference 2023 appeared first on MPN Education Foundation.
- 13th Joyce Niblack Memorial Conference – February 18/19, 2023by JOANN MANNINO at 11:08 pm
The post 13th Joyce Niblack Memorial Conference – February 18/19, 2023 appeared first on MPN Education Foundation.
- Dr. Mesa: Evolving Therapy of MPNs – 2022by JOANN MANNINO at 10:46 pm
The post Dr. Mesa: Evolving Therapy of MPNs – 2022 appeared first on MPN Education Foundation.
- Hematocrit levels, white blood cell counts influence thrombosis risk in polycythemia veraby mpn_admin at 3:30 pm
Aaron T. Gerds, MD, MS, spoke with Healio about the REVEAL study, results of which were presented at this year’s European Hematology […]
- The Outcome of Fatherhood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms: A Single-Institution Experienceby mpn_admin at 3:29 pm
Abstract Background Fertility is a highly complex subject; it involves more than one individual and has profound psychological and economic […]
- Introducing PAN’s Newly Expanded Transportation Fundby mpn_admin at 2:31 pm
The PAN Foundation today announced an expansion of its transportation fund, providing up to $500 per year to help eligible patients access […]
- GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bnby mpn_admin at 2:15 pm
04/13/2022 Sierra Oncology’s differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis […]
- AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosisby mpn_admin at 5:20 pm
–          Navitoclax is being studied in myelofibrosis, a rare, difficult-to-treat blood cancer […]
- Women’s History Month – Jamile Shammo, MDby mpn_admin at 8:06 pm
Dr Jamile Shammo is a Professor of Medicine and Pathology in the Department of Internal Medicine, Division of Hematology, Oncology and […]
- Women’s History Month – Linda Resar, MDby mpn_admin at 11:08 pm
Dr. Linda Resar, is a Professor of Medicine at Johns Hopkins Medicine, where she studies molecular mechanisms leading to cancer, blood […]
- Women’s History Month – Angela Fleischman, MD, PhDby mpn_admin at 3:59 pm
Dr. Angela Fleischman is an Associate Professor of Medicine in the Division of Hematology/Oncology at the University of California, […]
- Adelaide researchers discover potential treatment for myelofibrosisby mpn_admin at 5:12 pm
By Ethan Rix by abc net Australia Posted Thu 24 Mar 2022 at 8:20pm  When Bruce Glover was diagnosed with a rare blood cancer, he […]
- Updates from ASH with Dr. Mesaby JOANN MANNINO at 5:55 pm
The post Updates from ASH with Dr. Mesa appeared first on MPN Education Foundation.
- Dr. Mesa discusses FDA approval of Besremi/ropegby JOANN MANNINO at 8:42 pm
The post Dr. Mesa discusses FDA approval of Besremi/ropeg appeared first on MPN Education Foundation.